Transcranial Photobiomodulation With Patients With Parkinson's Disease

Not Applicable

Completed

• Conditions: Parkinson Disease

• Registration Number: NCT06729125
• Lead Sponsor: Al-Zaytoonah University of Jordan

Brief Summary

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is a progressive and disabling disease with significative impact on quality of life. Since it has no cure, available treatment is targeted to improve the symptoms due to a lack of dopamine in the central nervous system. The aim of the study was to see how transcranial photobiomodulation (tPBM) helped patients with Parkinson's disease.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-12-05
• Study First Submitted QC: 2024-12-10
• Study First Posted: 2024-12-11
• Study Start: 2024-12-15
• Primary Completion: 2025-03-20
• Status Verified: 2025-04
• Study Completion: 2025-04-03
• Last Update Submitted: 2025-04-06
• Last Update Posted: 2025-04-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• idiopathic PD,
• Hoehn & Yahr stage I-IV,
• independent gait with or without technical assistance
• stable parkinsonian medication for at least a month before the study star.

Exclusion Criteria

• comorbidities that affect balance or walking,
• other neurological pathologies besides PD,
• chronic diseases not medically controlled and participation in another physiotherapy program or sport activity during the intervention period or in the month before starting the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
posture stability	8 weeks	The Biodex Balance System (Biodex Medical Systems Inc, USA) Will be used to assess the limit of stability (overall, forward and backward) pre- and post-treatment.

Secondary Outcome Measures

Name	Time	Method
functional activity	8 weeks	The modified Parkinson activity scale (mPAS) consist of 14 items arranged on to three domains: chair transfer (2 items), gait akinesia (6 items) and bed mobility (6 items)

Trial Locations

Locations (1)

Al Zaytoonah University; 🇯🇴 Amaan, Jordan